NoviaHealth, a new company dedicated to the commercialisation of advanced probiotic ingredients for improved health, has been launched as a spin-off from Synbiotic Health, a market leader in the discovery of probiotic ingredients.
As a new and independent company, NoviaHealth will provide probiotic concentrates, custom probiotic blends and turnkey contract development and manufacturing services to the dietary supplement market.
NoviaHealth will operate from laboratories, offices and a new manufacturing facility in Madison, Wisconsin, that is scheduled to open in the second quarter of 2024.
Synbiotic Health will continue to function as an independent company providing microbiome R&D services, and NoviaHealth will have the exclusive right to commercialise future Synbiotic Health discoveries, including new strains and other intellectual property.
NoviaHealth was created with the mission to deliver complete solutions to the dietary supplement market, from ideation to launch, in a service-first culture.
The new company will provide the market with benefits and services that CPG brands have been asking for, including product concept ideation, codevelopment, custom formulations and low minimum order quantities, all within a culture of operational transparency.
Tim Brummels, President and CEO of NoviaHealth, stated: “There’s a reason why Novia is part of our name. It references our new way of thinking and a new way of operating."
"Novia is derived from the Latin word novus, meaning new, which reflects our constant pursuit of new ideas and innovative solutions. The creation of NoviaHealth represents our evolution to meet the needs of the market."
"As an innovative, boutique CDMO, we will cater to our customers with the services they need most: complete support from ideation to launch, a high-performing portfolio of probiotics, and a very strong commitment to personalised service.”
